Megan J. Ehret, PharmD, MS, BCPP
Addressing unique medication adherence issues for patients with schizophrenia
Focus on lurasidone: A new atypical antipsychotic for the treatment of schizophrenia
Lurasidone, a new-generation atypical antipsychotic, has been approved by FDA for the treatment of schizophrenia and is under investigation for the treatment of bipolar disorder. This article will discuss the clinical pharmacology, clinical trials, adverse events, drug interactions, dosing and administration, and formulary considerations.
Iloperidone: A novel atypical antipsychotic for the treatment of schizophrenia
Iloperidone, a new-generation atypical antipsychotic, is currently under investigation for the treatment of schizophrenia. In 4 separate phase 3 trials, iloperidone has demonstrated efficacy in treating schizophrenia, with total Positive and Negative Symptom Scale (PANSS) scores decreasing by a range of 8 to 14 points depending on the iloperidone dose.

Poll